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Abstract
Background: As part of the SAFE strategy, mass antibiotic treatments are useful in controlling the ocular strains of
chlamydia that cause trachoma. The World Health Organization recommends treating at least 80% of individuals per
community. However, the role of antibiotic coverage for trachoma control has been poorly characterized.
Methodology/Principal Findings: In a collection of cluster-randomized clinical trials, mass oral azithromycin was
administered to 40 villages in Ethiopia. The village prevalence of ocular chlamydia was determined before treatment, and at
two and six months post-treatment. The mean prevalence of ocular chlamydia was 48.9% (95% CI 42.8 to 55.0%) before
mass treatments, decreased to 5.4% (95% CI 3.9 to 7.0%) at two months after treatments (p,0.0001), and returned to 7.9%
(95% CI 5.4 to 10.4%) by six months after treatment (p=0.03). Antibiotic coverage ranged from 73.9% to 100%, with a mean
of 90.6%. In multivariate regression models, chlamydial prevalence two months after treatment was associated with
baseline infection (p,0.0001) and antibiotic coverage (p=0.007). However, by six months after treatment, chlamydial
prevalence was associated only with baseline infection (p,0.0001), but not coverage (p=0.31).
Conclusions/Significance: In post-hoc analyses of a large clinical trial, the amount of endemic chlamydial infection was a
strong predictor of chlamydial infection after mass antibiotic treatments. Antibiotic coverage was an important short-term
predictor of chlamydial infection, but no longer predicted infection by six months after mass antibiotic treatments. A wider
range of antibiotic coverage than found in this study might allow an assessment of a more subtle association.
Citation: Lakew T, Alemayehu W, Melese M, Yi E, House JI, et al. (2009) Importance of Coverage and Endemicity on the Return of Infectious Trachoma after a
Single Mass Antibiotic Distribution. PLoS Negl Trop Dis 3(8): e507. doi:10.1371/journal.pntd.0000507
Editor: Albert I. Ko, Weill Medical College of Cornell University, United States of America
Received April 27, 2009; Accepted July 24, 2009; Published August 25, 2009
Copyright:  2009 Lakew et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the International Trachoma Initiative, the Bernard Osher Foundation, That Man May See, the Peierls Foundation, the Bodri
Foundation, the Harper Inglis Trust, the South Asia Research Fund, Research to Prevent Blindness, and grants U10 EY016214, R21 AI 55752, and 1K23 EY019071-01
from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jeremy.keenan@ucsf.edu
Introduction
The World Health Organization (WHO) recommends the SAFE
strategy (eyelid surgery, mass antibiotics, facial hygiene promotion, and
environmental improvement) for the control of trachoma, the world’s
leading infectious cause of blindness[1]. Mass antibiotic treatments
target the ocular strains of chlamydia that cause trachoma, and are a
crucial component of the SAFE strategy. A single dose of oral
azithromycin is clearly effective in eliminating infection from individual
cases[2,3]. A mass distribution of azithromycin to an entire community
has been shown to dramatically reduce the prevalence of infection.
Unfortunately, infection returns in areas with hyper-endemic tracho-
ma[4–6]. Theoretically, repeated treatments can progressively reduce
the prevalence of, and even eliminate, infection[7]. However, models
suggest that in severely affected areas, treatment would have to be
given frequently and to a large portion of the population[8,9].
There have been few studies examining the role of antibiotic
coverage for trachoma control, aside from the observation that
mass antibiotic treatments with high coverage have resulted in a
considerable reduction in ocular chlamydia prevalence, and even
elimination of infection[10,11]. Many think that low antibiotic
coverage may play a crucial role in persistent ocular chlamydial
infection[12]. Currently, the WHO recommends a goal of 80%
antibiotic coverage for trachoma programs[1]. However, the
relationship between antibiotic coverage and treatment efficacy at
the community level has not been well characterized. Mathemat-
ical models have suggested that at higher antibiotic coverages, less
frequent mass treatments will be required, and elimination will
occur in a shorter period of time[7,9]. It is not clear what level of
coverage will be necessary, or whether different guidelines will be
necessary for more severely affected areas[5,8]. Here we assess
how the prevalence of infection two and six months post-treatment
www.plosntds.org 1 August 2009 | Volume 3 | Issue 8 | e507is dependant on the antibiotic coverage and the amount of
endemic infection at baseline.
Methods
The Committee on Human Research at the University of
California, San Francisco approved this post-hoc analysis of
existing data, and approved the use of verbal informed consent,
which was obtained by local Amharic-speaking health workers
from all study participants at the time of each procedure. Verbal
consent was performed due to the high amount of illiteracy in the
region.
As part of a larger, multiple arm, group-randomized trial, 40
villages were enrolled in the Gurage Zone of southern Ethio-
pia[6,7,13,14]. Although the 40 villages were distributed between
five study arms, they received identical treatment and monitoring
for the initial six months, the results of which are reported here.
An initial census of the study area was performed by trained local
health workers; the names of all permanent residents in each
village were recorded. The population of villages ranged from 122
to 976, with a median of 368 persons (interquartile range 243 to
502). Those aged 1 year and older were offered a single dose of
directly observed, oral azithromycin (1g in adults or 20 mg/kg in
children). Pregnant women and those allergic to macrolides were
offered a six-week course of topical 1% tetracycline ointment
(applied twice daily to both eyes and not directly observed).
Antibiotic coverage was defined as the proportion of permanent
residents eligible for treatment in the village (i.e., those $1 year of
age) who accepted directly observed treatment with oral
azithromycin or not-directly observed topical tetracycline, as
determined from the baseline census by the health workers who
distributed the antibiotics. Individuals known to have either moved
permanently or died between the census and the scheduled
treatment were not included in the denominator. Children aged
1–5 years were monitored at baseline, two months, and six months
post-treatment, as described below. After the six month monitor-
ing, some communities received biannual treatment, some annual
treatment, and some no further treatment unless infection
surpassed a pre-assigned level. The results of these trials are
published elsewhere[6,7,13,14].
All children aged 1–5 years in treated villages were assessed for
the presence of ocular chlamydia infection at baseline (pre-
treatment), two months post-treatment, and six months post-
treatment. A dacron swab was passed firmly across the right upper
tarsal conjunctiva three times, rotating between each pass.
Examiners wore new gloves for each study subject. All samples
were kept at 4uC in the field and frozen at 220uC within six hours.
The swabs were shipped at 4uC to San Francisco where they were
stored at 270uC until processed. The AMPLICOR PCR test
(Roche Diagnostics, Branchburg, NJ) was used to detect
chlamydial DNA. Pre-treatment samples were tested individually,
and post-treatment samples were analyzed as pooled samples.
PCR pooling is a well established, cost-effective technique for
diagnosis of genital and ocular chlamydia[15,16]. Post-treatment
samples from the same village were randomized and pooled into
groups of 5, with a possible remainder pool of 1–4 samples. Each
pool was then tested according to the AMPLICOR protocol. If
two-thirds or more of the pools were positive, the individual
samples were re-pooled randomly into groups of two and re-
processed to allow more accurate estimation[16]. If PCR of any
pool was equivocal, then all samples from the pool were
individually re-tested. As per the AMPLICOR protocol, an
internal control was performed for each pool to rule out the
presence of PCR inhibitors. Any inhibitory pools were re-tested,
and if still inhibitory, the samples were tested individually. While
samples necessarily were diluted in the pooling process, this is not
thought to significantly impact the sensitivity of the test[17]. The
prevalence of ocular chlamydia infection in each village was
obtained by maximum likelihood estimation[7]. The number of
positive individual samples most likely to have resulted in the
observed pooled PCR results was chosen as the estimate for that
village (Mathematica 5.0, Wolfram Research Inc., Champaign,
IL).
All statistical analyses were conducted at the village level using
village prevalence; no individual-level data was used in this study.
This is appropriate, since trachoma interventions occur at the
village level, and treatment success is measured at the village level,
not at the individual level. The distribution of the prevalence of
antibiotic coverage was depicted with a kernel density plot, using
the Epanechnikov kernel function, the Sheather-Jones plug-in
bandwidth estimate, and upper boundary correction using the
renormalization method. The Wilcoxon signed rank test was used
to compare the prevalence of infection at baseline with two
months, and at two months with six months. The Spearman rank
order correlation coefficient and 95% confidence interval was
calculated for pairwise combinations of baseline infection,
antibiotic coverage, infection at two months after treatment, and
infection at six months after treatment. Multivariate regression was
performed to assess the relationship between the prevalence of
infection post-treatment with antibiotic coverage and endemic
(baseline) infection. Linear regression models were constructed
using the prevalence of chlamydial infection at either two or six
months as the response variable, and baseline prevalence of
infection and antibiotic coverage as explanatory variables, using
the robust variance calculation based on the HC3 heteroskedas-
ticity consistent covariance matrix estimator, due to concerns
about heteroskedastic residuals[18]. Infection prevalence at all
time points was square-root transformed to minimize hetero-
skedasticity and maximize normality of the residuals from the
linear regression analysis (analyzed by plotting the residuals vs. the
fitted values and residuals vs. the predictors; in addition, no
heteroskedasticity was demonstrated with the Cook-Weisberg test,
Author Summary
Trachoma, caused by ocular chlamydia infection, is the
most common infectious cause of blindness in the world.
The World Health Organization (WHO) recommends the
SAFE strategy (eyelid surgery, antibiotics, facial hygiene,
environmental improvements) for trachoma control. Oral
antibiotics reduce the transmission of ocular chlamydia,
but re-infection of treated individuals is common. There-
fore, the WHO recommends annual mass antibiotic
treatments to the entire village. The success of treatment
is likely based on many factors, including the antibiotic
coverage, or percentage of villagers who receive antibiot-
ics. However, no studies have analyzed the importance of
antibiotic coverage for the reduction of ocular chlamydia.
Here, we performed multivariate regression analyses on
data from a clinical trial of mass oral antibiotics for
trachoma in a severely affected area of Ethiopia. At the
relatively high levels of antibiotic coverage in our study,
coverage was associated with post-treatment infection at
two months, but not at six months. The amount of
infection at baseline was strongly correlated with post-
treatment infection at both two and six months. These
results suggest that in areas with severe trachoma treated
with relatively high antibiotic coverage, increasing cover-
age even further may have only a short-term benefit.
Coverage and Endemicity in Trachoma Control
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Francia test, using a significance level of 0.05). Linearity of the
predictors in the model was adequate, as assessed with component-
plus-residual plots comparing the linear fit of the predictor to the
LOWESS curve. Multivariate regression models were constructed
including the multiplicative interaction term for antibiotic
coverage and baseline infection, but interaction terms were not
significant, and therefore not included in the final model. All
statistical analyses were performed with STATA 10.0 (Statacorp,
College Station, TX).
Results
The mean number of children ages 1–5 examined in each
village at baseline was 54.2 (95% CI 45.7 to 62.8). No villages were
lost to follow up. The mean pre-treatment prevalence of infection
in 1–5 year old children among the 40 study villages was 48.9%
(95% CI 42.8 to 55.0%). Antibiotic coverage data was present for
38 of the study villages, and ranged from 73.9% to 100%, with a
mean of 90.6% (95% CI 88.7 to 92.4%). As is evident in a density
plot, the majority of villages had an antibiotic coverage between
80–100% (Figure 1). Two months after treatment, infection
decreased significantly from baseline, to a mean of 5.4% (95% CI
3.9 to 7.0%), p,0.0001. Between two and six months after
treatment, the village prevalence of infection increased, to a mean
of 7.9% (95% CI 5.4 to 10.4%), p=0.03, compared to two
months).
Using Spearman’s test of correlation, prevalence of infection in
1–5 year old children at two months was strongly correlated with
baseline infection (rs=0.62, 95% CI 0.39 to 0.78), and moderately
correlated with antibiotic coverage (rs=20.31, 95% CI 20.58 to
0.01). The prevalence of infection in 1–5 year old children at six
months was strongly correlated with infection at baseline (rs=0.55,
95%CI 0.28 to 0.73) and at two months (rs=0.73, 95% CI 0.54 to
0.85), but only weakly correlated with antibiotic coverage
(rs=20.16, 95% CI 20.46 to 0.17).
Multivariate regression models demonstrated that at two
months after treatment, chlamydial infection in 1–5 year old
children was predicted by both baseline chlamydial infection and
antibiotic coverage (R
2=0.53, Table 1). By six months after
treatment, baseline chlamydial infection remained a significant
predictor of chlamydial infection, but antibiotic coverage did not
(R
2=0.35, Table 1). Because the square root transformation of the
response variable made the regression coefficients difficult to
interpret, we used the models to calculate the role of antibiotic
coverage in predicting post-treatment chlamydia in a hypothetical
community, holding the baseline prevalence of infection constant
at 48.9% (the mean baseline infection in this study). As depicted in
Figure 2, antibiotic coverage had a greater effect in predicting
chlamydial prevalence at two months compared to six months,
evident from the steeper curve and narrower 95% confidence
intervals.
Discussion
Mathematical models and clinical trials have demonstrated the
importance of vaccine coverage for conveying immunity on a
population[19,20]. Analogously, antibiotic coverage has been
touted as an important determinant in the long-term success of
the WHO’s mass antibiotic treatments for trachoma[5,7,9,21,22].
Some have suggested that a single mass antibiotic treatment may
prevent infection from returning, if given to a sufficiently large
proportion of the community[23,24]. In this study, coverage was
important at two months after treatment, but we were unable to
demonstrate its importance at six months.
In our study, baseline infection was a significant predictor of
chlamydial infection at both two months and six months, whereas
antibiotic coverage predicted chlamydial infection only at two
months. Thus, in this severely affected area, the amount of
endemic infection appears to be a stronger determinant of
chlamydial infection than antibiotic coverage. This may be the
case for at least three reasons. First, communities with more initial
infection will tend to have more residual infection after an
incomplete mass treatment, as demonstrated by mathematical
models[8]. Secondly, re-infection after mass treatments likely
occurs more rapidly in areas with severe trachoma, due to
underlying transmission characteristics in these areas, such as poor
hygiene and sanitation, travel to untreated communities, genetic
variation among chlamydial strains and a myriad of other risk
factors[25–27]. This suggests that in the long run, the forces that
result in the return of ocular chlamydia into severely affected
communities may overwhelm any temporary advantage conferred
by high antibiotic coverage[26,28,29]. Third, children under 1
year of age were not treated with oral antibiotics in this study, and
may therefore have served as a reservoir for infection. It is possible
that the level of endemic infection is an indicator of infection in
Figure 1. Kernel density estimate showing the distribution of
antibiotic coverage. Antibiotic coverage data was available for 38 of
40 villages. The density plot was computed using the Epanechnikov
kernel function, Sheather-Jones plug-in bandwidth estimate, and upper
boundary correction using the renormalization method.
doi:10.1371/journal.pntd.0000507.g001
Table 1. Multivariate regression models analyzing the
prevalence of baseline infection and antibiotic coverage as
predictors for the prevalence of chlamydial infection at two
months and 6 months after treatment.
Response variable Explanatory variable b(SE) p-value R
2
Infection at two months Baseline infection 0.59 (0.10) ,0.0001 0.53
Antibiotic coverage 20.64 (0.22) 0.007
Infection at six months Baseline infection 0.70 (0.13) ,0.0001 0.35
Antibiotic coverage 20.36 (0.35) 0.31
Regression analyses used HC3 robust variance calculation, with the square root
transformation of chlamydial infection at baseline, two months post-treatment,
and six months post-treatment.
doi:10.1371/journal.pntd.0000507.t001
Coverage and Endemicity in Trachoma Control
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relationship between endemic infection and post-treatment
infection may indicate that chlamydial transmission from this
young age group was more important than antibiotic coverage in
predicting the prevalence of chlamydial infection after treatment.
If chlamydial infection does depend more on endemic infection
than antibiotic coverage, this would not support devoting more
resources to increasing the target antibiotic coverage from WHO
guidelines, which currently recommend 80% antibiotic coverage.
It is important to note that this regression model should not be
extrapolated outside the range of our data; therefore, this
conclusion may be generalizable only to severely affected areas
with relatively high coverage. It is possible that antibiotic coverage
may carry more importance in areas with milder trachoma and
slower return of chlamydia after mass treatments.
This analysis supports the theory that treatment frequency and
duration could be tailored to areas based on pre-treatment
prevalence. Currently, the WHO recommends three annual mass
treatments to trachoma-endemic areas, with re-evaluation after the
third treatment[1]. This strategy has proven very successful in nearly
eliminating infection in an area with a modest-moderate amount of
trachoma[30]. However, fewer treatments may be sufficient in
communities with hypoendemic trachoma and low pre-treatment
chlamydial prevalence[24]. In contrast, communities with hyperen-
demic trachoma and high pre-treatment chlamydial prevalence may
require a greater number of treatments, or more frequent treatments,
as suggested by mathematical models[7–9,13] and clinical tri-
als[13,14,31]. In this study, chlamydial prevalence after mass
antibiotic treatments was strongly predicted by the pre-treatment
prevalence of infection, which supports the idea that villages could be
stratified by pre-treatment chlamydial prevalence and offered a
tailored mass antibiotic treatment regimen. Further research is
needed to determine whether this could be a feasible strategy.
Few previous studies have addressed the question of antibiotic
coverage for ocular chlamydia, aside from noting the success of
mass antibiotic efforts with high coverage[10,11,32]. However, our
findings are consistent with a study of mass azithromycin in
multiple villages in the Gambia[29]. In the Gambian study, re-
emergence of chlamydial infection in a subset of villages could not
be explained by antibiotic coverage, which averaged 83% among
the villages. These findings are consistent with the possibility that
at the 80% antibiotic coverage target currently recommended by
the WHO, other predictors become more important than
differences in coverage.
There are several limitations of this study. We focused on one
component of the SAFE strategy: mass antibiotic distributions, and
are unable to comment on the role of antibiotic coverage in the
setting of other trachoma interventions. We analyzed predictors of
chlamydial infection at the community level, and therefore cannot
make any conclusions regarding individuals in the community.
However, individual-level data are not particularly helpful for
trachoma programs, which make treatment decisions based on
community indicators of trachoma. There was a relatively short
surveillance time of six months, at which point some of the
communities had scheduled re-treatments. Migration in the study
areawas not studied. The range of antibioticcoverage wasrelatively
narrow, which may have decreased the likelihood of finding a
significant effect of antibiotic coverage in the regression models, and
may decrease the generalizability of the study. Finally, since
communities in this study were not randomized to a pre-specified
antibiotic coverage, unmeasured confounders may have affected the
regression analyses. We would expect, however, that these
confounders would have biased toward an association between
antibiotic coverage and infection, since those communities where it
is difficult to attain high antibiotic coverage may also have
conditions that enhance the transmission of ocular chlamydia.
Figure 2. Predicted chlamydial infection after a single mass azithromycin treatment, with varying levels of antibiotic coverage. Post-
treatment chlamydial prevalence in 1–5 year old children was calculated for a hypothetical community treated with a single mass azithromycin
treatment, in which 48.9% of 1–5 year old children were infected at baseline. Antibiotic coverage was significantly associated with post-treatment
infection at two months (2A; R
2=0.53, p=0.007), but not at six months (2B; R
2=0.35, p=0.31). The upper and lower curves are the boundaries of the
95% confidence interval for the predicted mean.
doi:10.1371/journal.pntd.0000507.g002
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mass azithromycin for trachoma, we found that antibiotic
coverage predicted chlamydial infection at two months after
treatment, but not at six months after treatment. Far more
important was baseline chlamydial infection, which was a strong
predictor of infection at both two months and six months. This
suggests that the WHO’s recommendation of 80% antibiotic
coverage is reasonable, and that trying to further increase
antibiotic coverage may be less successful than targeting more
intensive treatments to highly prevalent communities. Clinical
trials in which communities are randomized to different antibiotic
coverage levels will be important to more fully characterize the
relationship between antibiotic coverage and chlamydial infection
after mass antibiotic treatments.
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